Candid, with $370M, sets out to prove bispecifics' worth in autoimmune disease
Candid Therapeutics, a biotech startup, launched with $370 million to develop T-cell engager drugs for inflammatory diseases, acquiring rights to two cancer drug prospects from Vignette Bio and TRC 2004. CEO Ken Song believes T-cell engagers are a better solution for autoimmune diseases than cell therapy due to lower production costs and easier administration. The company plans to start clinical trials for autoimmune conditions next year.
Reference News
Candid Therapeutics, a biotech startup, launched with $370 million to develop T-cell engager drugs for inflammatory diseases, acquiring rights to two cancer drug prospects from Vignette Bio and TRC 2004. CEO Ken Song believes T-cell engagers are a better solution for autoimmune diseases than cell therapy due to lower production costs and easier administration. The company plans to start clinical trials for autoimmune conditions next year.